High Efficacy Achieved in the Case of Lymphomatoid Granulomatosis with Targeted Therapies

Buyuksimsek M, Ogul A, Yetisir AE, Koseci T, Duman BB, Tohumcuoglu M, Kesen O, Cil T, Arbag HC and Sumbul HE

Department of Medical Oncology, University of Health Sciences, Adana Health Practice and Research Center, Turkey
Department of Internal Medicine, University of Health Sciences, Adana Health Practice and Research Center, Turkey

^*Correspondance to: Mahmut Buyuksimsek 

 PDF  Full Text Case Report | Open Access

Abstract:

Objective and Importance: In this article we present a case of the lymphomatoid granulomatosis which good response achieved with targeted therapies. Clinical Case: A 71-year-old female patient presented with complaints of upper respiratory tract and weight loss. A mass lesion which filled the right hemithorax almost completely was detected and there were multiple lymph nodes in the mediastinum in the tomography imaging. Trucut biopsy was performed and pathology report was compatible with CD20+, CD30+ lymphoproliferative disease, Lymphomatoid Granulomatosis (LG). The patient was planned to be treated with CD20 and CD30 targeting agents, rituximab, brentuximab vedotin, and the antineoplastic agent bendamustine. After 3 cures of treatment, almost complete regression was detected in the lung mass lesion and mediastinal lymph nodes. Discussion: High-grade LG cases are considered to be aggressive high-grade lymphomas and require aggressive treatments. We wanted to present this case to emphasize the importance of using targeted agents in LG patients for whom treatment modalities are not clear.

Keywords:

Cite the Article:

Buyuksimsek M, Ogul A, Yetisir AE, Koseci T, Duman BB, Tohumcuoglu M, et al. High Efficacy Achieved in the Case of Lymphomatoid Granulomatosis with Targeted Therapies. Clin Case Rep Int. 2022; 6: 1261.